In a notable update for dermatologic and consumer health, the U.S. Food and Drug Administration (FDA) released a press statement disclosing their authorization of the use of bemotrizinol as an active ingredient in over-the-counter (OTC) sunscreens. This decision marks the first addition of a new sunscreen active component to the OTC monograph since the late 1990s, signaling renewed momentum in U.S. sunscreen innovation.
Long-Awaited Regulatory Shift
The FDA’s action follows years of criticism that the U.S. sunscreen market has lagged behind international counterparts in adopting newer ultraviolet (UV) filters. Bemotrizinol, already widely used in Europe and other regions, has an established history of safe and effective use. The agency completed its review and finalized the decision within seven months of releasing its proposed order, reflecting a more streamlined regulatory approach enabled by recent legislative changes.
Safety and Efficacy Profile
Bemotrizinol provides broad-spectrum protection against both UVA and UVB radiation, a key factor in preventing skin cancer and photoaging. According to FDA findings, the ingredient demonstrates minimal systemic absorption when applied topically. Based on available evidence, it has been classified as “generally recognized as safe and effective” (GRASE) for individuals aged six months and older, aligning it with existing sunscreen standards.
Regulatory Modernization
This approval was processed under the updated OTC monograph framework established by the CARES Act, which allows for more efficient review through administrative orders rather than traditional rulemaking. The change is intended to accelerate the introduction of safe, evidence-based nonprescription products to the market.
The process began with an application from DSM Nutritional Products LLC, which requested approval for bemotrizinol at concentrations up to 6%. After issuing a proposed order in December 2025 and opening a public comment period through January 2026, the FDA reviewed stakeholder input before issuing its final determination.
Broader Policy Context
The move is consistent with broader federal efforts to modernize consumer health regulations. Officials have emphasized that expanding available sunscreen ingredients could improve product performance, enhance consumer trust, and promote competition within the marketplace.
Implications for Clinical Practice and Public Health
For healthcare providers, the addition of bemotrizinol may expand recommendations for sun protection, particularly for patients requiring stable, broad-spectrum coverage. Its inclusion could also encourage the development of new formulations with improved cosmetic acceptability, potentially supporting better patient adherence.
From a public health standpoint, increasing the diversity and effectiveness of sunscreen products remains a critical strategy in reducing UV-related skin damage and skin cancer incidence.
Bottom line: The FDA’s approval of bemotrizinol represents a pivotal step toward modernizing sunscreen regulation in the United States, closing a decades-long gap and potentially reshaping the OTC photoprotection landscape.
